Mandate

Vinge advises Calliditas Therapeutics in connection with the listing on Nasdaq Stockholm’s main market

Vinge advises Calliditas Therapeutics AB (publ) (“Calliditas Therapeutics”) in connection with the listing of the company’s shares on Nasdaq Stockholm’s main market. Trading in Calliditas Therapeutics’ shares on Nasdaq Stockholm commences today, 29 June 2018.

The price in the offering was set at SEK 45 per share, which corresponds to a value of the total number of shares in the company upon completion of the offering of SEK 1,593 million, assuming full exercise of the over-allotment option in the offering. Assuming full exercise of the over-allotment option, the value of the offering amounts to approximately SEK 747 million before transaction costs. 

Calliditas is a specialty pharmaceutical company based in Stockholm, Sweden, focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications in which the company can partially or completely participate in the commercialization efforts. The company is focused on the development and commercialization of the product candidate Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy.
  
Vinge’s team primarily consists of Dain Hård Nevonen, Johan Larsson, Maria Schultzberg, Sofie Bjärtun, Sabina Kihlberg, Filip Öhrner, Victor Ericsson and William Kåge. 

Related

Vinge has advised SBB and Sveafastigheter in connection with an exchange offer

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (SBB) and Sveafastigheter AB in connection with an exchange offer directed to investors in SBB’s outstanding bonds, whereby investors exchanged senior and hybrid bonds in SBB for new senior bonds issued in Sveafastigheter AB. The existing bonds were partly issued under SBB’s EMTN programme, partly on a standalone basis. Following the transaction, the investors have been slotted in under Swedish bond terms on a standalone basis.
July 09, 2024

Vinge advises Polar Structure AB in connection with its issuance of EUR 81 million senior secured notes through a majority owned subsidiary

Vinge advises Polar Structure AB, a leading developer and owner of infrastructure, in connection with its issuance of EUR 81 million senior secured notes through a majority owned subsidiary. The proceeds will be used to finance the construction of a railway outside Boden, which will connect the existing iron ore line (Sw. Malmbanan) with H2 Green Steel’s new facility for large-scale production of green steel at Boden Industrial Park.
July 04, 2024

Vinge advises Bergs Timber AB (publ) and Bitus A

Vinge advises Bergs Timber AB (publ) and Bitus AB in connection with the divestment of the Fågelfors pellets business to J. Rettenmeier & Söhne. The Fågelfors pellets factory is based in Fågelfors in Högsby. The acquisition is subject to customary regulatory approvals.
July 03, 2024